Citation Impact
Citing Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
2007 Standout
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma
2002
Hallmarks of Cancer: The Next Generation
2011 Standout
Inhibition of lymphangiogenesis‐related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270
2004
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival
1999
Inflammation and cancer
2002 StandoutNature
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis
2002
HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
2005 StandoutNobel
Targeting hypoxia in cancer therapy
2011 Standout
Identification of a Selectivity Determinant for Inhibition of Tumor Necrosis Factor-α Converting Enzyme by Comparative Modeling
2003
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer
1998
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
2002
Drug penetration in solid tumours
2006 Standout
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
2001
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease
2000
Lung Cancer
2008 Standout
Translating cancer research into targeted therapeutics
2010 Nature
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
2002
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Strategies for MMP inhibition in cancer: innovations for the post-trial era
2002
Imaging angiogenesis of genitourinary tumors
2010
Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11
2002
Vascular Endothelial Growth Factor and Angiogenesis
2004 Standout
Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?
2011
Angiogenesis in cancer and other diseases
2000 StandoutNature
Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study
1997
Lymphangiogenesis in development and human disease
2005 StandoutNature
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Putting tumours in context
2001 Standout
Cancer genes and the pathways they control
2004 Standout
Antibody therapy of cancer
2012 Standout
Recent advances in MMP inhibitor design
2006
Angiogenesis in life, disease and medicine
2005 StandoutNature
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
2002
Remodelling the extracellular matrix in development and disease
2014 Standout
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer
2006
Clonal Genetic Alterations in the Lungs of Current and Former Smokers
1997
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
2010
Nonchannel drug targets in atrial fibrillation
2004
Hematopoietic Stem-Cell Transplantation
2006 Standout
Inflammation and cancer: back to Virchow?
2001 Standout
Vascular-specific growth factors and blood vessel formation
2000 StandoutNature
A Simple Enantioconvergent and Chemoenzymatic Synthesis of Optically Active α‐Substituted Amides
2011 StandoutNobel
Overview of the clinical efficacy of investigational anticancer drugs
2003
Physiology of Local Renin-Angiotensin Systems
2006 Standout
Small cell lung cancer: the importance of the extracellular matrix
2004
Hypoxic Tumors and Their Effect on Immune Cells and Cancer Therapy
2010
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
2009 Standout
bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma
1998
Organic Switches for Surfaces and Devices
2012 StandoutNobel
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Chylous ascites: A collective review
2000 Standout
Biomarkers in Heart Failure
2008 Standout
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Advances in Malignant Mesothelioma
2005 Standout
Tumorigenesis and the angiogenic switch
2003 Standout
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
2000
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
2000 StandoutNobel
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
1999
Molecular Imaging in Cancer
2006 Science
Luminescent Chemodosimeters for Bioimaging
2012 Standout
Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer.
2000
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Matrix Metalloproteinases
2002
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
1999 StandoutScience
Characterization of hematopoietic progenitor mobilization in protease-deficient mice
2004
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
2001
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
1998
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
1999
A New Initiative on Precision Medicine
2015 Standout
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma
2004
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts
2009
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
1997
n-Propyl gallate activates hypoxia-inducible factor 1 by modulating intracellular oxygen-sensing systems
2008 StandoutNobel
Mass Transport in Tumors: Characterization and Applications to Chemotherapy
1980
Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure
2003
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
1999
Ongoing trials with matrix metalloproteinase inhibitors
2000
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies
2010
Dose translation from animal to human studies revisited
2007 Standout
Works of D C Talbot being referenced
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study
2007
Chylous ascites in Kaposi's sarcoma: a case report
1992
PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER
1996
Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000
2003
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
2001
Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results.
1996
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
1999
Some Observations on the Reversibility of Methotrexate Toxicity in Normal Proliferating Tissues2
1977